Cellectis is a pioneering biopharmaceutical company dedicated to the development of innovative immunotherapies, specifically focusing on gene-edited engineered CAR T-cells, known as UCART. With a mission to revolutionize cancer treatment through advanced genome engineering, Cellectis leverages over ...